View Older Stories View More Recent Stories
-
Scotiabank Reiterates Sector Perform Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Approves Additional $4B Buyback Program
-
Stifel Reiterates Hold Rating on Vertex (VRTX)
-
Bernstein on Vertex (VRTX): 'We'd Sit Tght' Following Yesterday's Stock Sell-Off
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
Wolfe Research Downgrades Vertex (VRTX) to Peerperform
-
Vertex (VRTX) PT Raised to $462 at Bernstein SocGen Group
-
Stifel Reiterates Hold Rating on Vertex (VRTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $442 at Scotiabank
-
Leerink Partners Downgrades Vertex (VRTX) to Market Perform 'on Lower Pain Projections'
-
After-hours movers: Palantir, Ford, Clorox and more
-
Vertex Pharma (VRTX) Misses Q1 EPS by 20c; raises guidance
-
Vertex Pharma (VRTX) call put ratio 1.2 calls to 1 put into quarter results
-
Vertex Pharma (VRTX) call put ratio 5.8 calls to 1 put into quarter results
-
UBS Reiterates Buy Rating on Vertex (VRTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Cantor Fitzgerald Assumes Vertex (VRTX) at Overweight
-
BMO Capital on Vertex (VRTX): 'Growth Continues as We Look Ahead to 1Q Earnings'
-
Pharma stocks slide after Trump signals tariffs on sector
-
Vertex Pharma (VRTX) announces European Commission approval of KAFTRIO label expansion
-
Vertex (VRTX) PT Raised to $420 at RBC Capital; 'Alyftrek Could Be Off To a Good Start'
-
Canaccord Genuity Reiterates Hold Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Announces Program Updates for Type 1 Diabetes Portfolio
-
DA Davidson Reiterates Buy Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Announces UK MHRA Approval of ALYFTREK
-
Vertex Pharma (VRTX) Receives CHMP Positive Opinion for Expanded Label for KAFTRIO in Combination With Ivacaftor
-
Vertex (VRTX) PT Raised to $408 at RBC Capital
-
DA Davidson Reiterates Buy Rating on Vertex (VRTX)
-
TD Cowen Reiterates Buy Rating on Vertex (VRTX): 'VRTX is a Top 2025 L.C. Biotech Pick'
-
Vertex (VRTX) PT Raised to $520 at Truist on 'Incrementally Positive Commercial Outlook'
-
Vertex (VRTX) PT Raised to $459 at Morgan Stanley
-
BMO Capital Expects '2 New Launches to Drive 2025 PnL' for Vertex (VRTX)
-
Vertex (VRTX) PT Raised to $450 at Scotiabank
-
Piper Sandler: 'Vertex (VRTX) Firing on All Cylinders'
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Raised to $444 at Bernstein After Journavx and Alyftrek Launches
-
Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
-
Vertex Pharma (VRTX) call put ratio 5.1 calls to 1 put with a focus on February 14 weekly calls into quarter results
-
Vertex Pharma (VRTX) call put ratio 2.8 calls to 1 put into quarter results
-
Vertex (VRTX) PT Raised to $550 at H.C. Wainwright
-
Vertex (VRTX) PT Raised to $545 at BMO Capital Following Suzetrigine's approval
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) announces FDA Approval of JOURNAVX
-
FDA Approves Vertex's (VRTX) Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
-
Vertex (VRTX) PT Lowered to $533 at Piper Sandler on Adjusted Q424 Casgevy Revenue Estimates
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Zai Lab (ZLAB) and Vertex (VRTX) Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
-
Vertex (VRTX) PT Raised to $401 at RBC Capital; 'We Would Look for a More Compelling Entry Point'

